TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03138863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BALT GoldbBAL2 Detachable Balloon
Description: Latex balloon, with radio-opaque inclusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter System
Description: 100 cm tapered micro-catheter
Study: NCT06453616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hello bundle
Description: Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)
Study: NCT06242028

Intervention type: DRUG
Intervention: Group P
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.

Intervention type: DRUG
Intervention: Group S
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
Study: NCT04924322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
Study: NCT04754087

Intervention type: DEVICE
Group type: OTHER
Intervention: Vivacit-E and Longevity (HXLPE) Liners
Description: This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
Study: NCT05268380

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19, TB and HIV diagnosis
Description: GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19, TB and HIV diagnosis
Description: GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
Study: NCT04939155

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 mRNA vaccine
Description: mRNA vaccine for COVID
Study: NCT05412433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Level
Description: Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel
Description: Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel
Description: Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care
Study: NCT04912167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
Study: NCT06334679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Gel Packet Application
Description: Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
Study: NCT06634420

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NTLA-2002
Description: CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline IV Administration
Description: The administration of intravenous (IV) normal saline
Study: NCT05058391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Elaprase IV infusion.
Study: NCT04626713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface
Description: Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
Study: NCT04982133

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment
Description: At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment
Description: At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk.
Study: NCT05779163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-033 for Injection
Description: Initial dose - MTD; Q2W; intravenous infusion
Study: NCT01543750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05381220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
Study: NCT05338047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegfilgrastim
Description: Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
Study: NCT06197009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SCT650C
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCT650C
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCT650C
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCT650C
Description: Administered SC
Study: NCT05176600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games
Description: Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games
Description: Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
Study: NCT05660655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG Oral Tablet
Description: baricitinib 4 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 2 MG
Description: baricitinib 4mg once daily in group A
Study: NCT05108779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF32004
Description: In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
Study: NCT05734157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral PTA with a drug coated balloon
Description: Peripheral artery angioplasty
Study: NCT04724187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: it is prostaglandin E1 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: it stimulates uterine contractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: it stimulates uterine contractions
Study: NCT05662826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based Social Physical Activity
Description: Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
Study: NCT06563011

Intervention type: OTHER
Group type: OTHER
Intervention: Counselling
Description: Tailored Dietary Counselling
Study: NCT05698186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thero2-01S22
Description: Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thero2-01S22
Description: Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study: NCT05459597

Intervention type: DRUG
Intervention: antiepileptic drugs
Description: phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Study: NCT06559670

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: - Collection and analysis of blood samples
Study: NCT04820920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP
Description: LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
Study: NCT05286047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum CCFM1029
Description: Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take one capsule containing maltodextrin daily at bedtime.
Study: NCT04819594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil aromatabs ®
Description: 100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
Study: NCT05422391

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3 day caloric restriction/metabolic reset
Description: Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
Study: NCT06561009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-BAFFR CART
Description: Anti-BAFFR CART
Study: NCT06559566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG
Description: The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
Study: NCT05009992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)
Study: NCT06559566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BCT
Description: The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
Study: NCT05760144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel implant
Description: The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
Study: NCT06553664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat with Vibrabot capsules for at least 7 weeks
Description: Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
Study: NCT05009992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)
Study: NCT05622799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Medicine Training Program
Description: A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
Study: NCT06017102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wired magnetic assisted capsule endoscopy
Description: once
Study: NCT06257212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine (Danish strain 1331)
Description: Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMR Vaccine
Description: Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous saline + intradermal saline at inclusion and after 3 months.
Study: NCT05009992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Given orally (PO)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06323408

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue, blood, cerebrospinal-spinal fluid
Description: Processing, analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue, blood, cerebrospinal-spinal fluid
Description: Processing, analysis
Study: NCT04917874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open Label Topical Beremagene Geperpavec (B-VEC)
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Study: NCT06517680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tight control management
Description: Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up
Description: Patients are monitored according to standard practice
Study: NCT05349435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezagepras
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezagepras
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Investigational drug
Study: NCT06017102

Intervention type: DEVICE
Group type: OTHER
Intervention: esophagogastroduodenoscopy
Description: once
Study: NCT06788249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine only
Description: The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
Study: NCT06417411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily use of low dose aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Daily use of low dose aspirin.
Study: NCT05635565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized goal training
Description: This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized goal training with educational strategies
Description: This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
Study: NCT05009992

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06246357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor
Description: \[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
Study: NCT05345665

Intervention type: OTHER
Group type: OTHER
Intervention: Echography
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with an only echography.

Intervention type: OTHER
Group type: OTHER
Intervention: Echography and neurostimulation
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Echography and neurostimulation
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Echography, neurostimulation and active mobilization
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.

Intervention type: OTHER
Group type: OTHER
Intervention: Echography, neurostimulation and active mobilization
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.

Intervention type: OTHER
Group type: OTHER
Intervention: Echography, neurostimulation and active mobilization
Description: Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.